Veracyte Inc
NASDAQ:VCYT
Veracyte Inc
Gross Profit
Veracyte Inc
Gross Profit Peer Comparison
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Veracyte Inc
NASDAQ:VCYT
|
Gross Profit
$248.1m
|
CAGR 3-Years
48%
|
CAGR 5-Years
33%
|
CAGR 10-Years
39%
|
|
Abbvie Inc
NYSE:ABBV
|
Gross Profit
$36.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Gross Profit
$20.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Gross Profit
$19.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Gross Profit
$8.6B
|
CAGR 3-Years
16%
|
CAGR 5-Years
27%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Gross Profit
$11.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
See Also
What is Veracyte Inc's Gross Profit?
Gross Profit
248.1m
USD
Based on the financial report for Dec 31, 2023, Veracyte Inc's Gross Profit amounts to 248.1m USD.
What is Veracyte Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
39%
Over the last year, the Gross Profit growth was 27%. The average annual Gross Profit growth rates for Veracyte Inc have been 48% over the past three years , 33% over the past five years , and 39% over the past ten years .